Losartan/hydrochlorothiazide

Drug Profile

Losartan/hydrochlorothiazide

Alternative Names: Cozaar Plus; Cozaarex D; Hizaar; Hyzaar; Lorzaar Plus; Losartan potassium/hydrochlorothiazide; Losazid; MK 954H; MK-0954A; Neo Lotan Plus; Preminent

Latest Information Update: 19 Jun 2012

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Banyu; Merck Sharp & Dohme; Neopharmed; sigma-tau SpA
  • Class Antihypertensives; Benzothiadiazines; Biphenyl compounds; Imidazoles; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 26 Jan 2012 Generic equivalent available in Canada for Hypertension
  • 12 Jan 2012 Merck completes enrolment in its phase III trial for Hypertension in Japan (NCT01307046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top